- Home
- RNXT vs SLGL Comparison
RNXT vs SLGL Comparison
Compare RNXT & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNXT
- SLGL
- Stock Information
- Founded
- RNXT 2012
- SLGL 1997
- Country
- RNXT United States
- SLGL Israel
- Employees
- RNXT N/A
- SLGL N/A
- Industry
- RNXT Biotechnology: Pharmaceutical Preparations
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- RNXT Health Care
- SLGL Health Care
- Exchange
- RNXT Nasdaq
- SLGL Nasdaq
- Market Cap
- RNXT 44.6M
- SLGL 69.1M
- IPO Year
- RNXT 2021
- SLGL 2018
- Fundamental
- Price
- RNXT $1.26
- SLGL $24.15
- Analyst Decision
- RNXT Strong Buy
- SLGL
- Analyst Count
- RNXT 2
- SLGL 0
- Target Price
- RNXT $7.50
- SLGL N/A
- AVG Volume (30 Days)
- RNXT 626.0K
- SLGL 32.7K
- Earning Date
- RNXT 11-12-2025
- SLGL 11-14-2025
- Dividend Yield
- RNXT N/A
- SLGL N/A
- EPS Growth
- RNXT N/A
- SLGL N/A
- EPS
- RNXT N/A
- SLGL N/A
- Revenue
- RNXT $662,000.00
- SLGL $23,931,000.00
- Revenue This Year
- RNXT $2,988.37
- SLGL N/A
- Revenue Next Year
- RNXT $300.60
- SLGL $31.17
- P/E Ratio
- RNXT N/A
- SLGL N/A
- Revenue Growth
- RNXT N/A
- SLGL 264.86
- 52 Week Low
- RNXT $0.75
- SLGL $4.01
- 52 Week High
- RNXT $1.69
- SLGL $30.00
- Technical
- Relative Strength Index (RSI)
- RNXT 59.62
- SLGL 53.62
- Support Level
- RNXT $1.06
- SLGL N/A
- Resistance Level
- RNXT $1.45
- SLGL $24.85
- Average True Range (ATR)
- RNXT 0.12
- SLGL 2.15
- MACD
- RNXT 0.03
- SLGL -1.38
- Stochastic Oscillator
- RNXT 65.45
- SLGL 80.50
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.